LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Newly Created Prion Seen As Exciting Research Tool

By LabMedica International staff writers
Posted on 20 Jun 2018
Image: Synthetic human prions accumulating in the brain of humanized transgenic mice (Photo courtesy of Case Western Reserve University School of Medicine).
Image: Synthetic human prions accumulating in the brain of humanized transgenic mice (Photo courtesy of Case Western Reserve University School of Medicine).
A neurodegenerative disease research team has created an exciting new research tool by synthesizing a fully functional, infectious human prion, similar to that causing the fatal progressive neural disorder Creutzfeldt-Jakob disease.

Heretofore, attempts to generate infectious synthetic human prions have not yet been successful, blocking the pathway to comprehensive understanding of human prion diseases such as sporadic Creutzfeldt-Jakob disease (sCJD).

In the June 4, 2018, online edition of the journal Nature Communications, investigators at the Case Western Reserve University School of Medicine (Cleveland OH, USA) described studies conducted to repair this lack, by showing that human prions could be synthesized in vitro from bacterially expressed recombinant human PrP (prion protein) in a reaction seeded with sCJD MM1 prions in the presence of a novel cofactor, ganglioside GM1.

The investigators reported that the synthetic human prions that they had made were infectious to transgenic mice expressing non-glycosylated human prion protein, causing neurologic dysfunction after 459 and 224 days in the first and second passage, respectively. The neuropathology, replication potency, and biophysical profiling suggested that a novel, particularly neurotoxic human prion strain had been created.

By comparing the structural organization of these synthetic human prions with that of parent sCJD MM1 prions and noninfectious human prion protein amyloid, the investigators identified domains in PrP that were important for the initiation of replication in vivo, i.e. their infectivity, and for targeting of different anatomical brain structures.

“This accomplishment represents a watershed,” said senior author Dr. Jiri G. Safar, professor of pathology and neurology at the Case Western Reserve School of Medicine. “Until now our understanding of prions in the brain has been limited. Being able to generate synthetic human prions in a test tube as we have done will enable us to achieve a much richer understanding of prion structure and replication. This is crucial for developing inhibitors of their replication and propagation throughout the brain, which is essential for halting prion-based brain disease.”

“Our findings explain at the structural level the emergence of new human prions and provide a basis for understanding how seemingly subtle differences in misfolded protein structure and modifications affect their transmissibility, cellular targeting, and thus manifestation in humans,” said Dr. Safar.

Related Links:
Case Western Reserve University School of Medicine

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Laboratory Software
ArtelWare

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more